By Ben Glickman


Medtronic said its combined system for use during treatment of atrial fibrillation reached its safety and efficacy endpoints in a trial.

The medical-device company said that the Affera Mapping and Ablation System with Sphere-9 Catheter, an ablation and mapping system, showed higher freedom from AFib compared with the control arm of the trial and had a comparable safety profile.

The Affera system with Sphere-9 catheter was specifically being evaluated in cases of persistent AFib, which makes up 30% to 50% of patients.

The company said it had recently filed for approval of the combined system in the U.S.


Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

05-17-24 1703ET